Daping Hospital and the Research Institute of Surgery of the Third Military Medical University: Carcinoma, Non-Small-Cell Lung trials

The registry lists 16 Carcinoma, Non-Small-Cell Lung studies with Daping Hospital and the Research Institute of Surgery of the Third Military Medical University as lead sponsor. 6 are open to participants now and 0 have results posted.

Phase 2 5Phase 3 2Phase 4 1No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Postbiotics Ameliorate Cachexia in Patients With Non-small-cell Lung CancerNot yet recruitingNCT07185308Not applicable
• Enteral Nutrition With L-Carnitine for Cachexia in Non-Small Cell Lung CancerNot yet recruitingNCT07035444Not applicable
• Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLCNot yet recruitingNCT06436144Phase 2
• To Explore the Effect of Immune-induced Stereotactic Body Radiotherapy (SBRT) on Reversing Immunoresistance in Stage IIIc/IV Non-small Cell Lung Cancer (NSCLC)Not yet recruitingNCT06154967Not applicable
• The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLCNot yet recruitingNCT06117644
• Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and DabrafenibNot yet recruitingNCT05988697
• AI Models for Predicting Occult Pleural Dissemination in NSCLCCompletedNCT07065422
• PPIO-006 Primary Tumor Resection for IVa NSCLCCompletedNCT06232967
• Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients.Status unknownNCT06018688Phase 2
• Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC PatientsCompletedNCT04184921Phase 2
• Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLCCompletedNCT03543683Phase 2
• Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC)Status unknownNCT03532698
• First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR MutationStatus unknownNCT02883543Phase 3
• Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung CancerStatus unknownNCT02480634Phase 4
• Phase Ⅲ Trial of WBRT Versus Erlotinib Concurrent Whole-brain Radiation Therapy as first-line Treatment for Patients With Multiple Brain Metastases From Non-small-cell Lung Cancer(ENTER): a Multicentre, Open-label, Randomised StudyCompletedNCT01887795Phase 3
• Combination of Metformin With Gefitinib to Treat NSCLCCompletedNCT01864681Phase 2